Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral NTX-1955 brain effects study in healthy adults
NL-OMON60260Phase 1Completed
- Sponsor
- Newleos Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of RO7308480 in generalized anxiety disorder (GAD), sponsored by Newleos Therapeutics. Primary endpoint: Primary endpoint(s). Started Jun 2025; status: completed.
02
Drugs
RO7308480
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NL-OMON60260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60260.